Skip to main content
PMC home page
Alzheimer's Research & Therapy logoLink to Alzheimer's Research & Therapy
. 2018 Oct 12;10:106. doi: 10.1186/s13195-018-0435-2

Exome sequencing in an Italian family with Alzheimer’s disease points to a role for seizure-related gene 6 (SEZ6) rare variant R615H

Lara Paracchini 1, Luca Beltrame 1, Lucia Boeri 2, Federica Fusco 3, Paolo Caffarra 4, Sergio Marchini 1, Diego Albani 3,✉, Gianluigi Forloni 3
PMCID: PMC6182820  PMID: 30309378

Abstract

Background

The typical familial form of Alzheimer’s disease (FAD) accounts for about 5% of total Alzheimer’s disease (AD) cases. Presenilins (PSEN1 and PSEN2) and amyloid-β (A4) precursor protein (APP) genes carry all reported FAD-linked mutations. However, other genetic loci may be involved in AD. For instance, seizure-related gene 6 (SEZ6) has been reported in brain development and psychiatric disorders and is differentially expressed in the cerebrospinal fluid of AD cases.

Methods

We describe a targeted exome sequencing analysis of a large Italian kindred with AD, negative for PSEN and APP variants, that indicated the SEZ6 heterozygous mutation R615H is associated with the pathology.

Results

We overexpressed R615H mutation in H4-SW cells, finding a reduction of amyloid peptide Aβ(1–42). Sez6 expression decreased with age in a mouse model of AD (3xTG-AD), but independently from transgene expression.

Conclusions

These results support a role of exome sequencing for disease-associated variant discovery and reinforce available data on SEZ6 in AD models.

Electronic supplementary material

The online version of this article (10.1186/s13195-018-0435-2) contains supplementary material, which is available to authorized users.

Keywords: Alzheimer’s disease, SEZ6, Exome sequencing, Rare variants

Background

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder whose onset is mostly sporadic [1]. The genetic background has a major role in AD, and DNA variants may contribute, ranging from predisposing risk factors (having from medium to large effect size, such as the ε4 allele of the APOE gene) [2] to full penetrant causal mutations in a few genes, namely presenilins (PSEN1 and PSEN2) and the amyloid-β (A4) precursor protein (APP) [3, 4]. PSEN1/2 and APP gene mutations have been linked to early-onset, autosomal dominant familial forms of Alzheimer’s disease (FAD) [5, 6]. Recently, large-scale whole-exome sequencing has found rare variants reported to contribute to AD risk, such as in the PLCG2, ABI3, and TREM2 genes [7]. These findings indicate the involvement in familiar forms of AD of variants belonging to genes other than PSEN1/2 and APP, which may have a causal or predisposing role, as recently reported for SORL1 gene [8].

We report an Italian family with several cases of AD (having an onset between 60 and 70 years) negative for PSEN1/2 or APP mutations and whose available affected members were found to bear SEZ6 gene rare missense variant R615H. We describe the genetic, in vitro, and in vivo findings further supporting a role for SEZ6 in AD molecular mechanisms.

Methods

Family and patient description

The family’s pedigree is reported in Fig. 1. We extracted DNA for exome sequencing analysis from the members indicated by the code PR (seven subjects). We had clinical details about three generations after the founder. Ten dementia cases were reported in the whole pedigree, with an additional member having Parkinson’s disease. The age of onset of neurodegenerative disorders ranged from 60 to 70 years. In the first generation, one early-onset dementia case was reported (age at death, 48 years). In the second generation, 8 of 25 siblings (32%) were diagnosed with AD, with an additional case in the third generation (age at onset 64 years). The remaining siblings of this generation were cognitively normal, aged between 35 and 45 years. Apolipoprotein E genotype (APOE) of available patients was in all cases ε3//ε3 apart from PR5 (ε3//ε4). Two siblings of PR5, diagnosed with AD, had dementia too, but they were unavailable for sampling.

Fig. 1.

Fig. 1

Open in a new tab

Pedigree of the Italian family with Alzheimer’s disease. We report clinical information for the last three generations after the founders. Sex, age at sampling, and apolipoprotein E (APOE) genotype of each available family member indicated in the box. The numbers next to subjects with dementia are the age at death. The roman numbers refer to the generation, with the progressive numbers linking to every generation sibling

Sporadic AD cases (n = 9) and cognitively normal elderly control subjects (n = 191) were included for independent evaluation of the SEZ6(R615H) variant frequency by digital droplet PCR (ddPCR).

Patients and healthy control subjects were recruited by the same clinical center, and AD was diagnosed according to international criteria. Healthy control subjects were spouses of patients coming to clinical attention, and they had no sign of neurodegenerative disorders and Mini Mental State Examination (MMSE) scores in the normal range [9].

Exome sequencing and APOE genotyping

The full-exome sequencing of 4811 disease-associated genes (clinical exome) was done starting from 50 ng of DNA diluted in Tris-HCl 10 mM, pH 8.5 (TruSight One Sequencing Panel; Illumina, San Diego, CA, USA), following the manufacturer’s instructions. Briefly, capture-based libraries were prepared by pooling three samples per time. The libraries’ concentrations were calculated using a Qubit® dsDNA High-Sensitivity Assay Kit (Invitrogen, Carlsbad, CA, USA), and the distribution of DNA fragments for each library was evaluated using a high-sensitivity DNA kit and a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Each library was run on a MiSeq platform (Illumina) using a 2 × 150-bp (300 cycles) configuration on a V3 sequencing flow cell.

Data analysis was performed according to best practice from the bioinformatics community. Raw sequence fragments (reads) were aligned to the reference genome (human, build hg19) with the Burrows-Wheeler alignment tool [10], followed by post-processing to recalibrate base call quality scores. Variants were called with the Genome Analysis Toolkit [11–13], using the HaplotypeCaller method, then annotated with the Variant Effect Predictor [14] and loaded into a specialized database [15] for further analysis. In silico mutation impact predictions were extracted from the dbNSFP database [16]. For computation, we used the “bcbio” pipeline (https://github.com/chapmanb/bcbio-nextgen) running on a high-performance computing platform as part of the Cloud4CaRE project. Data files were uploaded to the European Nucleotide Archive with accession number pending.

Selection of candidate variants used the following criteria: (a) depth at least 30×; (b) low frequency in the general population (< 1% in the 1000 Genomes Project); (c) at least a damaging predicted effect as reported from the dbNSFP; and (d) present in all family members affected by AD or their offspring. The APOE genotype was assessed by restriction fragment length polymorphism using the CfoI (Roche, Basel, Switzerland) restriction enzyme, as previously described [17].

Exome sequencing validation by digital droplet PCR

ddPCR experiments were done with the Bio-Rad QX200TM ddPCR system (Bio-Rad Laboratories, Hercules, CA, USA). The mutational assay for SEZ6 R615H was carried out according to the manufacturer’s instructions. Briefly, the TaqMan™ reaction mix, composed of 2× ddPCR Supermix for probes (no deoxyuridine triphosphate), 20× custom target probes for mut SEZ6 (probe sequence: CTACGGTCATGGGCAG-FAM), and 20× reference probes for wild-type SEZ6 (probe sequence: CTACGGTCGTGGGCA-HEX), was assembled at a final concentration of 450 nM and 20 ng of DNA in a volume of 20 μl. This reaction mix was added to a DG8 cartridge together with 60 μl of droplet generation oil for probe and used for droplet generation (QX200 droplet generator; Bio-Rad Laboratories). Droplets were then manually transferred to 96-well PCR plates and placed on a thermal cycler (T100 Thermal Cycler; Bio-Rad Laboratories) for the PCR amplification (thermal cycling conditions: 95 °C for 5 min, 95 °C for 30 s, and 55 °C for 1 min, 40 cycles; 98 °C for 10 min and 4 °C infinite; ramping rate 2 °C/s). The PCR plate was then transferred into the QX100 Droplet Reader for the fluorescence measurement of FAM and HEX probes. The numbers of positive and negative droplets were used to calculate the concentrations (copies/μl) of the target and the reference SEZ6 DNA sequence and their Poisson-based 95% CIs, excluding reactions with fewer than 10,000 total events (positive and negative) (QuantaSoft Analysis pro software 1.0.596; Bio-Rad Laboratories).

For family members and patients with sporadic AD, experiments were run in duplicate; the assay on the healthy population was run once.

Cloning and overexpression of SEZ6(R615H) in H4-SW cells

pSEZ6(R615H) cloning

Synthetic SEZ6(R615H) complementary DNA was provided by GenScript® in pCDNA3.1(+) vector and expanded in competent Escherichia coli cells (strain JM109; Promega, Madison, WI, USA). After purification, pSEZ6(R615H) was verified through the unique enzymatic restriction site PmeI (New England Biolabs, Hitchin, UK) and agarose gel electrophoresis.

Cell culture

H4-SW neuroglioma cells overexpressing human APP gene harboring the Swedish (SW) mutation [18] were grown in DMEM supplemented with 10% FBS, 2 mM l-glutamine, and antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin, 300 μg/ml hygromycin B, 10 μg/ml blasticidin-S).

Transient transfection was done using FuGENE® HD Transfection Reagent (Promega), and cells were selected with G418 (1200 μg/ml) after 48 h. For clonal selection of SEZ6(R615H) mutants, we picked colonies and analyzed DNA and protein extracts by PCR and Western blotting. Finally, a single-point mutation (G→A) leading to R615H substitution was checked by Sanger sequencing.

PCR for SEZ6(R615H) expression in H4-SW cells

PCR was run in a 20-μl mixture containing 50 ng of DNA, 0.5 mM each of forward primer 5′-CTACGGTCATGGGCAGGATTG-3′, which contains the single-point mutation (G→A), and the reverse oligonucleotide primer 5′- ATCATGGCAGGTGAGGATGGACT-3′ (metabion, Planegg, Germany); 1× PCR buffer 200 mM Tris-HCl, 500 mM KCl (Thermo Fisher Scientific, Waltham, MA, USA); 2.5 mM deoxynucleotide triphosphate (Thermo Fisher Scientific); 25 mM MgCl2 (Thermo Fisher Scientific); and 1 unit of Taq polymerase (Thermo Fisher Scientific). Amplification was done with an initial denaturation at 95 °C for 2 min, followed by 30 cycles of denaturation at 95 °C for 30 s, annealing at 61.7 °C for 30 s, extension at 72 °C for 70 s, and a final 5-min extension at 72 °C. The resulting PCR fragments were resolved by 1% agarose gel electrophoresis (Sigma-Aldrich, St. Louis, MO, USA).

Western blotting for SEZ6 overexpression in H4-SW cells

To assess protein overexpression of SEZ6 in H4-SW, protein extracts (18 μg) were separated on 8% SDS-PAGE gel and transferred to a nitrocellulose membrane. Blots were developed using horseradish peroxidase-conjugated secondary antibodies and the ECL chemiluminescence system (MerckMillipore, Burlington, MA, USA). All blots were normalized to α-tubulin and quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The following antibodies were used: anti-α-tubulin (1:7500; Abcam, Cambridge, UK) and anti-SEZ6 (1:1000; Aviva Systems Biology, San Diego, CA, USA).

DNA sequencing

To verify the presence of the single point mutation, we amplified the region containing the mutated base by PCR with forward primer 5′- GAGATCACAGACTCGGCTG-3′ and the reverse primer 5′- ATCATGGCAGGTGAGGATGGACT-3′ (metabion). The total amount of the generated PCR product was purified using the Wizard SV Gel PCR Clean-Up System (Promega) and sent to a Sanger sequencing service (Eurofins Genomics, Ebersberg, Germany). Output data were analyzed using Chromas Lite 2.01 software.

Aβ(1–42) and Aβ(1–40) in H4-SW cells expressing SEZ6(R615H)

A specific sandwich enzyme-linked immunosorbent assay (ELISA) (Immuno-Biological Laboratories Co., Gunma, Japan) was used to measure Aβ(1–42) and Aβ(1–40) concentrations in conditioned media from cultured H4-SW cells. A total of 150 × 103 cells were seeded in a six-well plate and grown overnight. The next day, the medium was changed, and after 48 h it was collected and immediately frozen after the addition of a broad-spectrum protease inhibitor (Sigma-Aldrich). An aliquot of 100 μl was used for ELISA to assess each value in triplicate.

Western blot analysis for Sez6 brain expression in 3xTG-AD mice

For Sez6 brain expression analysis, we used 3xTG-AD mice at 3, 9, and 19 months of age. This triple-transgenic model harbors human PS1(M146 V), APP(SW), and MAPT(P301L) transgenes, and starting from around 9 months of age, mice develop at brain level amyloid plaques and protein tau tangles. They also show early signs of synaptic dysfunction (starting from around 3 months of age), including long-term potentiation alteration [19]. Strain, age, and sex-matched nontransgenic animals were used as controls. Mice were housed at 23 °C room temperature with food and water ad libitum and a 12-h/12-h light/dark cycle. To obtain brain protein extract, the cortex was dissected from a single brain hemisphere and homogenized with ice-cold lysis buffer (pH 7.4) containing 1% Triton X-100 and a broad-range protease inhibitor cocktail. Cortex protein extract (20 μg) was analyzed as described above.

Statistics

Data analysis was done using Prism® version 6.0 software (GraphPad Software, La Jolla, CA, USA). In vitro and in vivo data were compared using one-way analysis of variance followed by Tukey’s post hoc test. Two-tailed levels of significance were used, and p < 0.05 was considered significant.

Results

Exome sequencing and APOE genotyping

To identify variants linked to dementia phenotype, we sequenced DNA samples from family members (healthy and AD cases) and unrelated patients with sporadic AD for a set of over 4000 genes reported as implicated in rare and genetic diseases. Our initial analysis identified 15,745 variants passing our quality control filters (variant depth 30× or more). Many of these were common polymorphisms present in the general population, so we selected only those rare in the European population (< 1% frequency), lowering the count to 612 (Additional file 1: Table S1).

To further narrow the search for variants of interest, we used in silico analysis to restrict our findings to those predicted as damaging for protein, finding 138 variants (Additional file 1: Table S1). The majority (96.4%) of possible damaging variants were common between both familial and sporadic AD samples. On the contrary, five variants (3.6%) were exclusive to the family samples (Table 1). In particular, a missense variant in the SEZ6 neuronal gene (c.1844G>A, R615H) was present only in the two available AD cases (PR1 and PR5) and in a first-degree relative (PR2, son of PR5). This variant was localized on one of the extracellular CUB domains of the protein [20, 21] and was predicted to have a high damaging potential (Combined Annotation Dependent Domain [CADD] score = 23). This prompted us to further focus on this variant.

Table 1.

Variants exclusive of family members and satisfying the filtering criteria

Chr Position Gene Variant Amino acid change (%) dbSNP
ID		 Found in (family code)
chr8 144,589,984 ZC3H3 c.1646
C > T		 p.Ser549
Leu		 0.5% rs
149,025,999		 PR 1, PR 2, PR 3, PR 4, PR 5, PR 7, PR 9
chr9 738,341 KANK1 c.3391
G > C		 p.Ala1131Pro 0.1% rs
180,816,986		 PR1, PR3, PR5
chr17 27,286,417 SEZ6 c.1844
G > A		 p.Arg615
His		 0.01% rs
371,753,097		 PR1, PR2, PR5
chr20 57,598,807 TUBB1 c.326
G > A		 p.Gly109
Glu		 0.2% rs
41,303,899		 PR1, PR2, PR3, PR5
chr22 24,717,509 SPECC1L c.562
C > T		 p.Leu188
Phe		 0.9% rs
56,168,869		 PR1, PR2, PR3, PR5, PR9
Open in a new tab

Chr Chromosome number

Percentage population frequency refers to data of the European population frequency derived from the 1000 Genomes Project at the time the manuscript was written. See the “Methods” section of text for further details. Chromosome positions refer to the hg19 assembly. The gene of interest (SEZ6) is highlighted in bold, and members affected with AD are Italic

Validation of exome sequencing SEZ6(R615H) data and variant screening in sporadic AD cases and healthy control subjects

Because the clinical exome results indicated a mutation in SEZ6 gene (c.1844G>A) as unique to the available family members with AD, we performed an independent validation to confirm the result. Using ddPCR, we tested for the SEZ6 variant in exome sequencing-positive family members (n = 3) and in sporadic AD cases (n = 9). To exclude the possibility that the polymorphic variant of SEZ6 identified could be detected at low frequency in the healthy population, too, the mutational assay was also done in a control group of 191 cognitively healthy people.

Figure 2 shows SEZ6 mutational analysis of three family members (PR1, PR2, and PR5) and a representative case of sporadic AD (PR11). Wild-type SEZ6 (green droplets) was detected in all samples, whereas mutated SEZ6 (blue) was detected only in the PR1, PR2 and PR5 samples. A single event with both wild-type and mutated SEZ6 was detected in PR11, probably a polymerase artifact.

Fig. 2.

Fig. 2

Open in a new tab

Digital droplet PCR validation of the exome sequencing data. For each patient, a 2D dot plot is shown, reporting the distribution of fluorescence (on the y-axis FAM amplitude, and on the x-axis HEX amplitude). FAM and HEX are the fluorescent dyes for the SEZ6 mutant and SEZ6 wild type, respectively. On the basis of the fluorescence measurements and the droplet distributions, thresholds (pink lines) were set to 5000 for the FAM channel (y-axis) and 3000 for the HEX channel (x-axis). Negative droplets (gray), FAM-positive (blue), HEX-positive (green), and FAM/HEX double-positive (orange) droplets are reported for the four cases and no-template control (NTC) analyzed. Each case represents the sum of independent reactions

Regarding a quantitative measure of the SEZ6 variant, Table 2 reports the concentration as the number of target molecules/μl of wild-type and mutant SEZ6 in all sporadic cases (n = 9), in family members (n = 3), and in healthy individuals (n = 191). Wild-type SEZ6 copies were detected in all groups. The means of wild-type SEZ6 copies/μl were 564, 258, and 130 in the healthy control group, sporadic AD cases, and family members, respectively. A high concentration of mutant SEZ6 was detected in family member samples. The simultaneous presence of the wild-type and the mutated form of SEZ6, with ratios (mutated SEZ6 to wild-type SEZ6) ranging from 0.95 to 1.1, confirmed the heterozygous nature of the SEZ6 C>T 27,286,417–27,186,418 substitution.

Table 2.

Mutant SEZ6 assay by digital droplet PCR in healthy control subjects, patients with sporadic Alzheimer’s disease, and family members

Healthy population (n = 191) Sporadic AD cases (n = 9) Family members (n = 3)
Sample Target Concentration
(copies/μl)		 Target Concentration
(copies/μl)		 Sample Target Concentration (copies/μl) Target Concentration (copies/μl) Sample Target Concentration
(copies/μl)		 Target Concentration (copies/μl) RATIO (mut/wt)
6 MUT SEZ6 N.D. WT SEZ6 17 PR3 MUT SEZ6 N.D. WT SEZ6 239 PR1 MUT SEZ6 116 WT SEZ6 103 1.13
7 MUT SEZ6 N.D. WT SEZ6 14 MUT SEZ6 N.D. WT SEZ6 226 MUT SEZ6 114 WT SEZ6 120 0.95
8 MUT SEZ6 N.D. WT SEZ6 11 PR4 MUT SEZ6 N.D. WT SEZ6 220 PR2 MUT SEZ6 130 WT SEZ6 130 1.00
9 MUT SEZ6 N.D. WT SEZ6 59 MUT SEZ6 N.D. WT SEZ6 224 MUT SEZ6 131 WT SEZ6 127 1.03
11 MUT SEZ6 N.D. WT SEZ6 41 PR6 MUT SEZ6 N.D. WT SEZ6 267 PR5 MUT SEZ6 149 WT SEZ6 153 0.97
12 MUT SEZ6 N.D. WT SEZ6 49 MUT SEZ6 N.D. WT SEZ6 261 MUT SEZ6 154 WT SEZ6 152 1.01
13 MUT SEZ6 N.D. WT SEZ6 36 PR7 MUT SEZ6 N.D. WT SEZ6 331
14 MUT SEZ6 N.D. WT SEZ6 29 MUT SEZ6 N.D. WT SEZ6 371
16 MUT SEZ6 N.D. WT SEZ6 29 PR8 MUT SEZ6 N.D. WT SEZ6 307
17 MUT SEZ6 N.D. WT SEZ6 27 MUT SEZ6 N.D. WT SEZ6 303
18 MUT SEZ6 N.D. WT SEZ6 43 PR9 MUT SEZ6 N.D. WT SEZ6 254
19 MUT SEZ6 N.D. WT SEZ6 30 MUT SEZ6 N.D. WT SEZ6 266
21 MUT SEZ6 N.D. WT SEZ6 35 PR10 MUT SEZ6 N.D. WT SEZ6 239
22 MUT SEZ6 N.D. WT SEZ6 53 MUT SEZ6 N.D. WT SEZ6 273
23 MUT SEZ6 N.D. WT SEZ6 37 PR11 MUT SEZ6 N.D. WT SEZ6 233
24 MUT SEZ6 N.D. WT SEZ6 45 MUT SEZ6 N.D. WT SEZ6 228
25 MUT SEZ6 N.D. WT SEZ6 32 PR12 MUT SEZ6 N.D. WT SEZ6 212
27 MUT SEZ6 N.D. WT SEZ6 26 MUT SEZ6 N.D. WT SEZ6 190
28 MUT SEZ6 N.D. WT SEZ6 47
29 MUT SEZ6 N.D. WT SEZ6 48
30 MUT SEZ6 N.D. WT SEZ6 30
34 MUT SEZ6 N.D. WT SEZ6 30
36 MUT SEZ6 N.D. WT SEZ6 49
38 MUT SEZ6 N.D. WT SEZ6 32
39 MUT SEZ6 N.D. WT SEZ6 34
41 MUT SEZ6 N.D. WT SEZ6 74
42 MUT SEZ6 N.D. WT SEZ6 43
44 MUT SEZ6 N.D. WT SEZ6 53
46 MUT SEZ6 N.D. WT SEZ6 64
51 MUT SEZ6 N.D. WT SEZ6 55
52 MUT SEZ6 N.D. WT SEZ6 19
53 MUT SEZ6 N.D. WT SEZ6 32
60 MUT SEZ6 N.D. WT SEZ6 46
61 MUT SEZ6 N.D. WT SEZ6 44
62 MUT SEZ6 N.D. WT SEZ6 64
64 MUT SEZ6 N.D. WT SEZ6 55
66 MUT SEZ6 N.D. WT SEZ6 45
67 MUT SEZ6 N.D. WT SEZ6 46
69 MUT SEZ6 N.D. WT SEZ6 48
70 MUT SEZ6 N.D. WT SEZ6 45
71 MUT SEZ6 N.D. WT SEZ6 67
72 MUT SEZ6 N.D. WT SEZ6 57
74 MUT SEZ6 N.D. WT SEZ6 54
89 MUT SEZ6 N.D. WT SEZ6 47
90 MUT SEZ6 N.D. WT SEZ6 78
91 MUT SEZ6 N.D. WT SEZ6 64.3
101 MUT SEZ6 N.D. WT SEZ6 283
112 MUT SEZ6 N.D. WT SEZ6 524
113 MUT SEZ6 N.D. WT SEZ6 1451
114 MUT SEZ6 N.D. WT SEZ6 962
115 MUT SEZ6 N.D. WT SEZ6 534
118 MUT SEZ6 N.D. WT SEZ6 527
119 MUT SEZ6 N.D. WT SEZ6 1691
120 MUT SEZ6 N.D. WT SEZ6 359
129 MUT SEZ6 N.D. WT SEZ6 186
130 MUT SEZ6 N.D. WT SEZ6 258
133 MUT SEZ6 N.D. WT SEZ6 232
135 MUT SEZ6 N.D. WT SEZ6 373
137 MUT SEZ6 N.D. WT SEZ6 319
144 MUT SEZ6 N.D. WT SEZ6 310
151 MUT SEZ6 N.D. WT SEZ6 396
152 MUT SEZ6 N.D. WT SEZ6 180
160 MUT SEZ6 N.D. WT SEZ6 574
162 MUT SEZ6 N.D. WT SEZ6 400
163 MUT SEZ6 N.D. WT SEZ6 142
164 MUT SEZ6 N.D. WT SEZ6 39
170 MUT SEZ6 N.D. WT SEZ6 96
179 MUT SEZ6 N.D. WT SEZ6 94
180 MUT SEZ6 N.D. WT SEZ6 27
182 MUT SEZ6 N.D. WT SEZ6 1406
184 MUT SEZ6 N.D. WT SEZ6 1994
185 MUT SEZ6 N.D. WT SEZ6 161
192 MUT SEZ6 N.D. WT SEZ6 14.5
193 MUT SEZ6 N.D. WT SEZ6 1740
197 MUT SEZ6 N.D. WT SEZ6 185
198 MUT SEZ6 N.D. WT SEZ6 250
199 MUT SEZ6 N.D. WT SEZ6 145
200 MUT SEZ6 N.D. WT SEZ6 132
202 MUT SEZ6 N.D. WT SEZ6 663
205 MUT SEZ6 N.D. WT SEZ6 658
206 MUT SEZ6 N.D. WT SEZ6 118
210 MUT SEZ6 N.D. WT SEZ6 103
212 MUT SEZ6 N.D. WT SEZ6 23
214 MUT SEZ6 N.D. WT SEZ6 385
215 MUT SEZ6 N.D. WT SEZ6 125
219 MUT SEZ6 N.D. WT SEZ6 223
223 MUT SEZ6 N.D. WT SEZ6 316
228 MUT SEZ6 N.D. WT SEZ6 109
233 MUT SEZ6 N.D. WT SEZ6 385
237 MUT SEZ6 N.D. WT SEZ6 767
240 MUT SEZ6 N.D. WT SEZ6 318
241 MUT SEZ6 N.D. WT SEZ6 15
243 MUT SEZ6 N.D. WT SEZ6 30
245 MUT SEZ6 N.D. WT SEZ6 166
247 MUT SEZ6 N.D. WT SEZ6 161
251 MUT SEZ6 N.D. WT SEZ6 164
253 MUT SEZ6 N.D. WT SEZ6 491
254 MUT SEZ6 N.D. WT SEZ6 772
255 MUT SEZ6 N.D. WT SEZ6 771
257 MUT SEZ6 N.D. WT SEZ6 148
261 MUT SEZ6 N.D. WT SEZ6 875
263 MUT SEZ6 N.D. WT SEZ6 381
267 MUT SEZ6 N.D. WT SEZ6 442
270 MUT SEZ6 N.D. WT SEZ6 368
275 MUT SEZ6 N.D. WT SEZ6 317
276 MUT SEZ6 N.D. WT SEZ6 368
277 MUT SEZ6 N.D. WT SEZ6 186
278 MUT SEZ6 N.D. WT SEZ6 63
279 MUT SEZ6 N.D. WT SEZ6 234
287 MUT SEZ6 N.D. WT SEZ6 99
293 MUT SEZ6 N.D. WT SEZ6 125
324 MUT SEZ6 N.D. WT SEZ6 605
325 MUT SEZ6 N.D. WT SEZ6 153
326 MUT SEZ6 N.D. WT SEZ6 692
327 MUT SEZ6 N.D. WT SEZ6 713
328 MUT SEZ6 N.D. WT SEZ6 391
332 MUT SEZ6 N.D. WT SEZ6 759
333 MUT SEZ6 N.D. WT SEZ6 661
337 MUT SEZ6 N.D. WT SEZ6 798
338 MUT SEZ6 N.D. WT SEZ6 903
340 MUT SEZ6 N.D. WT SEZ6 40
341 MUT SEZ6 N.D. WT SEZ6 274
342 MUT SEZ6 N.D. WT SEZ6 240
344 MUT SEZ6 N.D. WT SEZ6 209
345 MUT SEZ6 N.D. WT SEZ6 873
348 MUT SEZ6 N.D. WT SEZ6 2330
350 MUT SEZ6 N.D. WT SEZ6 387
351 MUT SEZ6 N.D. WT SEZ6 430
353 MUT SEZ6 N.D. WT SEZ6 360
360 MUT SEZ6 N.D. WT SEZ6 473
361 MUT SEZ6 N.D. WT SEZ6 553
362 MUT SEZ6 N.D. WT SEZ6 2470
363 MUT SEZ6 N.D. WT SEZ6 889
366 MUT SEZ6 N.D. WT SEZ6 1990
367 MUT SEZ6 N.D. WT SEZ6 452
368 MUT SEZ6 N.D. WT SEZ6 1736
369 MUT SEZ6 N.D. WT SEZ6 1436
375 MUT SEZ6 N.D. WT SEZ6 588
376 MUT SEZ6 N.D. WT SEZ6 544
377 MUT SEZ6 N.D. WT SEZ6 623
401 MUT SEZ6 N.D. WT SEZ6 803
404 MUT SEZ6 N.D. WT SEZ6 494
406 MUT SEZ6 N.D. WT SEZ6 200
407 MUT SEZ6 N.D. WT SEZ6 482
408 MUT SEZ6 N.D. WT SEZ6 105
409 MUT SEZ6 N.D. WT SEZ6 3260
418 MUT SEZ6 N.D. WT SEZ6 190
422 MUT SEZ6 N.D. WT SEZ6 1325
430 MUT SEZ6 N.D. WT SEZ6 772
434 MUT SEZ6 N.D. WT SEZ6 1233
435 MUT SEZ6 N.D. WT SEZ6 1844
440 MUT SEZ6 N.D. WT SEZ6 90
446 MUT SEZ6 N.D. WT SEZ6 745
451 MUT SEZ6 N.D. WT SEZ6 1366
453 MUT SEZ6 N.D. WT SEZ6 1185
454 MUT SEZ6 N.D. WT SEZ6 2950
466 MUT SEZ6 N.D. WT SEZ6 329
468 MUT SEZ6 N.D. WT SEZ6 681
493 MUT SEZ6 N.D. WT SEZ6 80
497 MUT SEZ6 N.D. WT SEZ6 154
499 MUT SEZ6 N.D. WT SEZ6 128
501 MUT SEZ6 N.D. WT SEZ6 1814
511 MUT SEZ6 N.D. WT SEZ6 547
512 MUT SEZ6 N.D. WT SEZ6 48.2
513 MUT SEZ6 N.D. WT SEZ6 40.8
514 MUT SEZ6 N.D. WT SEZ6 1019
519 MUT SEZ6 N.D. WT SEZ6 1382
520 MUT SEZ6 N.D. WT SEZ6 791
521 MUT SEZ6 N.D. WT SEZ6 1858
522 MUT SEZ6 N.D. WT SEZ6 2180
523 MUT SEZ6 N.D. WT SEZ6 1849
531 MUT SEZ6 N.D. WT SEZ6 2110
532 MUT SEZ6 N.D. WT SEZ6 3030
535 MUT SEZ6 N.D. WT SEZ6 1096
537 MUT SEZ6 N.D. WT SEZ6 1941
538 MUT SEZ6 N.D. WT SEZ6 78
539 MUT SEZ6 N.D. WT SEZ6 917
542 MUT SEZ6 N.D. WT SEZ6 1650
543 MUT SEZ6 N.D. WT SEZ6 937
545 MUT SEZ6 N.D. WT SEZ6 1423
546 MUT SEZ6 N.D. WT SEZ6 818
549 MUT SEZ6 N.D. WT SEZ6 1196
550 MUT SEZ6 N.D. WT SEZ6 716
558 MUT SEZ6 N.D. WT SEZ6 845
567 MUT SEZ6 N.D. WT SEZ6 724
570 MUT SEZ6 N.D. WT SEZ6 765
571 MUT SEZ6 N.D. WT SEZ6 2290
574 MUT SEZ6 N.D. WT SEZ6 790
575 MUT SEZ6 N.D. WT SEZ6 1399
578 MUT SEZ6 N.D. WT SEZ6 1293
580 MUT SEZ6 N.D. WT SEZ6 947
Open in a new tab

ND Not detectable

Alzheimer’s disease cases are underlined. For each group, patient code, digital droplet PCR target, and the calculated concentration (copies/μl) are reported. For the last group, the ratio, defined as concentration mutant SEZ6/concentration wild-type SEZ6, is also reported

Aβ peptide generation in H4-SW cells

Three different H4-SW stable clonal lines (C3, C4, and C13) transfected with a pCDNA3.1 plasmid coding for SEZ6(R615H) mutant were selected, and the presence of the variant at DNA level was confirmed by allele-specific PCR and sequencing (data not shown). The effect of the R615H substitution on Aβ(1–42) and Aβ(1–40) production by H4-SW cells was assessed in conditioned media from cultured H4-SW(R615H) in comparison to H4-SW cells (untransfected or mock-transfected with an empty pCDNA3.1 vector) (Fig. 3a). The mean concentration of released Aβ(1–42), normalized to cell total protein content, was significantly lower in C4 and C13 than in controls, whereas for the C3 line, there was a trend in the same direction (p = 0.07). The Aβ(1–40) assay showed no differences (Fig. 3b).

Fig. 3.

Fig. 3

Open in a new tab

Evaluation of SEZ6 relevance for Alzheimer’s disease (AD) mechanisms in in vitro and in vivo models. a Quantification by enzyme-linked immunosorbent assay of soluble amyloid-β 1–40 (Aβ1–40) in conditioned media from H4-SW clonal lines (C3, C4, and C13) overexpressing SEZ6(R615H). The amyloid peptide concentration was normalized to the total protein content of the producing cells of each replicate. Measures are the mean ± SD of three independent wells. H4-SW Untransfected control; Ø H4-SW control transfected with pCDNA3.1 empty vector. b Same as in (a) except for the assessment of Aβ1–42 soluble form. * p < 0.05; *** p < 0.001, one-way analysis of variance (ANOVA) and post hoc test; # p < 0.05 vs. C4 and p < 0.01 vs. C13, one-way ANOVA and post hoc test. c Representative Western blotting for Sez6 protein detection in brain cortical extract from 3xTG-AD mice. Mice were killed at ages 3, 9, or 19 months, and Sez6 expression was assessed in transgenic and matched nontransgenic (NTG) animals. Each group was composed of three mice, and every animal was loaded in duplicate in the SDS-PAGE experiment. * Unspecific signal. d Densitometric quantification of all Western blot analysis data for Sez6 protein cortical expression (n = 3 mice/group) using ImageJ software. Each signal was normalized to the corresponding α-tubulin band to control for unequal protein loading. Results are expressed as a percentage of the youngest group (3 months) * p < 0.05, one-way ANOVA and post hoc test. mo. Months from birth

Sez6 brain expression in 3xTG-AD mice

Given that few experimental data linked SEZ6 to AD, we also examined murine Sez6 expression in a transgenic line model of AD (3xTG-AD), in comparison with age-matched nontransgenic controls (NTG) (Fig. 3c and d). Mice were killed at ages ranging from 3 to 19 months, and Sez6 protein expression was assessed at brain cortical level. Sez6 protein markedly decreased with age, particularly between 3 and 19 months. However, this reduction was common to both the 3xTG-AD and NTG lines and thus not unique to the AD model.

Discussion

Pathogenic mutations in APP, PSEN1, or PSEN2 genes are linked to FAD [3, 4]. PSEN1 mutations are responsible for about 60% of the genetic cases of AD, and 286 pathogenic variants have been described in the three above-cited genes [22]. We report an Italian family with AD that we previously screened by denaturing high-performance liquid chromatography (data not shown) for APP, PSEN1, or PSEN2 mutations with no results. Considering that rare variants in other genes have been associated with AD [7], we decided to perform targeted exome-sequencing analysis that yielded a large number of variants; in order to identify those closely related to the disease, we employed a recursive filtering strategy. This strategy was based on the removal of high-frequency (> 1%) variants using a public database (1000 Genomes Project) with in silico prediction software (SIFT, PolyPhen2, CADD) to exclude potentially harmless mutations and focus on variants present in FAD but not sporadic AD samples. We gave priority to the SEZ6(R615H) variant among those reported in Table 1, considering that SEZ6 has already been reported as relevant for molecular mechanisms involved in AD pathogenesis, because it is a substrate of the BACE-1 enzyme (β-secretase), affects synapse formation, and is reduced in the cerebrospinal fluid of patients with AD, as revealed by a proteomic study [23–25]. SEZ6 gene mutations have been also reported in association with febrile seizures, and SEZ6 was proposed as a candidate gene for epilepsy [26, 27]. Moreover, SEZ6 mutations were found in cases of childhood-onset schizophrenia [28]. The rare variant R615H (rs371753097, C/T) was reported in the 1000 Genomes Project as absent in Toscani in Italy (TSI) population and had a frequency in the whole project of 0.0002 [29]. Another interesting genetic variant we found by exome sequencing that is deserving of attention is A1131P in the KANK1 gene [30], which was present in the two AD cases (PR1 and PR5) and in PR3, sibling of PR1. However, PR3 did not have dementia at sampling (age 67 years), and her clinical state is currently unchanged, even though we are not able to exclude a possible later onset. The human KANK1 gene (alias ANKRD15) was originally described to be a tumor suppressor in renal cell carcinoma, and it encodes an ankyrin repeat domain-containing protein (Kank). It belongs to a family of four homologous members that have a role in actin stress fiber formation and renal pathophysiology [31, 32]. There is no reported interaction of KANK1 with SEZ6 or AD-related genes. However, a role of KANK1 mutation or deletion was reported in cerebral palsy spastic quadriplegic type 2, a central nervous system developmental disorder [33]. Moreover, to the best of our knowledge, no data associate KANK1 with AD.

In our study’s family, we were able to correlate the AD pathology to R615H presence, which was found in the two available AD-affected members and one first-degree relative of an AD case, whose age at sampling in 2003 (PR2, 37 years) was far below the family age of onset (range, 60–70 years) to expect clinical signs. The current clinical diagnosis of PR2 (51 years) is unchanged. We also confirmed that R615H frequency is very low (< 1%) in the Italian population, because we were unable to detect the variant in 200 family-unrelated subjects.

Because it is a common finding that AD pathogenic mutations increase Aβ(1–42) peptide generation [34], we examined the effect of the R615H variant in a cell model in this respect. In the H4-SW line, we noticed a decrease in Aβ(1–42), whereas Aβ(1–40) was unchanged. However, the increase of Aβ(1–42) in association with FAD-linked mutations is not always replicated. In fact, some presenilin mutants with proved pathologic action did not increase Aβ(1–42) but acted on other Aβ peptide generation or even had no impact on this proteolytic cleavage. In the latter case, the hypothesis is that the mutation affects important functions of presenilin other than the γ-secretase activity [35, 36]. It is worth underlining that we found a peculiar biochemical effect of the PSEN1 mutation E318G that increased Aβ(1–40) only in cultured skin primary fibroblasts [17]. Our failure to detect an increase of Aβ(1–42) might depend on the reported role of SEZ6 protein as substrate for BACE-1 [23], so its overexpression may be competitive for APP in the cell model tested. We need further experiments to clarify the role of the R615H variant in this context.

Finally, we followed SEZ6 cortical expression in a mouse model of AD (3xTG-AD). Considering that it changed similarly in 3xTG-AD and control mice, we were unable to link this result to AD-specific patterns, but we did notice a decrease of SEZ6 protein with age, in agreement with this gene’s reported role in brain development [37, 38]. A damaging mutation (as R615H is predicted to be) may have an impact on the protein activity from birth, with possible neuropathologic outcomes, likely in combination with other triggering factors, also considering the reported role of SEZ6 in dendritic spine dynamics and cognition [39].

This study has limitations, mainly linked to the unavailability of genomic DNA from all the family’s AD-affected members alive at sampling. Moreover, we decided to use a targeted exome-sequencing strategy that, on one hand, gave us clinical data supporting a rational choice of candidate variants to be prioritized, but on the other hand, prevented us from ruling out that additional coding mutations in genes not included in our panel may be linked to AD phenotype, thus acting in synergy with SEZ6 (R615H).

Conclusions

In summary, by using a targeted exome-sequencing approach, we discovered a rare SEZ6 variant exclusive to AD members of a large Italian family carrying no typical FAD-linked mutations that might have a role in disease onset, in particular taking into account the already described involvement of SEZ6 in AD pathogenic mechanisms linked to amyloid-β (A4) precursor protein (APP) and brain physiology, even though the exact molecular pathway linking SEZ6 to AD is still unclear.

Additional file

Additional file 1: (85.9KB, xlsx)

Table reporting the sequencing results of DNA from PR family members and unrelated sporadic AD cases, including only rare variants in the European population (frequency less than 1%) [low frequency page]. The same reults were further filtered to show variants with predicted damaging action [predicted damage page]. (XLSX 85 kb)

Acknowledgements

We are grateful to the family that kindly participated in this study. We thank Judith Baggott for English-language editing.

Funding

This work was supported by Fondazione Italo Monzino (Milan, Italy).

Availability of data and materials

Exome sequencing data files were uploaded to the European Nucleotide Archive (https://www.ebi.ac.uk/ena) with accession numbers pending.

Authors’ contributions

LP performed the digital droplet PCR assay and exome sequencing. LBe alanyzed genomic data and produced bioinformatics output. FF and LBo prepared the H4-SW clonal lines and measured SEZ6 gene expression in transgenic mice. PC recruited the families with sporadic Alzheimer’s disease and control subjects. DA, SM, and GF drafted the manuscript. All authors critically revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All patients or their relatives gave informed consent for participation in this study, which was approved by the local ethics committee at Istituto di Neurologia, Università di Parma (PC), under the responsibility of Prof. Paolo Caffarra. Animal studies were run in compliance with national laws, regulations, and policies governing the care and use of laboratory animals: Italian Governing Law (D.lgs 26/2014; authorization no. 19/2008-A, issued March 6, 2008, by the Ministry of Health); Mario Negri institutional regulations and policies providing internal authorization for people conducting animal experiments (Quality Management System Certificate UNI EN ISO 9001:2008 registration no. 6121); the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (2011 edition), and European Union directives and guidelines (EEC Council Directive 2010/63/UE). The Statement of Compliance (Assurance) with the Public Health Service (PHS) Policy on Human Care and Use of Laboratory Animals was recently reviewed (September 9, 2014) and will expire on September 30, 2019 (Animal Welfare Assurance no. A5023-01, DL. vo 116/1992, Gazzetta Ufficiale, Suppl. 40, Feb.18, 1992; Circolare nr. 8, Gazzetta Ufficiale, July 14, 1994) and international laws and policies (EEC Council Directive 86/609, OJL 358, 1, Dec.12, 1987; NIH Guide for the Care and Use of Laboratory Animals 8th edition, 2011).

Consent for publication

Not applicable, because this article does not contain any individual person’s data, images, or videos.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Lara Paracchini, Email: lara.paracchini@marionegri.it.

Luca Beltrame, Email: luca.beltrame@marionegri.it.

Lucia Boeri, Email: lucia.boeri@polimi.it.

Federica Fusco, Email: federica.fusco@marionegri.it.

Paolo Caffarra, Email: caffarra@unipr.it.

Sergio Marchini, Email: sergio.marchini@marionegri.it.

Diego Albani, Phone: +39 02 39014594, Email: diego.albani@marionegri.it.

Gianluigi Forloni, Email: gianluigi.forloni@marionegri.it.

References

  • 1.Chandra V, Schoenberg BS. Inheritance of Alzheimer’s disease: epidemiologic evidence. Neuroepidemiology. 1989;8:165–174. doi: 10.1159/000110179. [DOI] [PubMed] [Google Scholar]
  • 2.Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]
  • 3.Brunkan AL, Goate AM. Presenilin function and gamma-secretase activity. J Neurochem. 2005;93:769–792. doi: 10.1111/j.1471-4159.2005.03099.x. [DOI] [PubMed] [Google Scholar]
  • 4.Bertram L, Tanzi RE. The current status of Alzheimer’s disease genetics: what do we tell the patients? Pharmacol Res. 2004;50:385–396. doi: 10.1016/j.phrs.2003.11.018. [DOI] [PubMed] [Google Scholar]
  • 5.Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature. 1995;375:754–760. doi: 10.1038/375754a0. [DOI] [PubMed] [Google Scholar]
  • 6.Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991;349:704–706. doi: 10.1038/349704a0. [DOI] [PubMed] [Google Scholar]
  • 7.Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet. 2017;49:1373–1384. doi: 10.1038/ng.3916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Thonberg H, Chiang HH, Lilius L, Forsell C, Lindström AK, Johansson C, et al. Identification and description of three families with familial Alzheimer disease that segregate variants in the SORL1 gene. Acta Neuropathol Commun. 2017;5:43. doi: 10.1186/s40478-017-0441-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944. doi: 10.1212/WNL.34.7.939. [DOI] [PubMed] [Google Scholar]
  • 10.Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26:589–595. doi: 10.1093/bioinformatics/btp698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–1303. doi: 10.1101/gr.107524.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–498. doi: 10.1038/ng.806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43:11.10.1–11.1033. doi: 10.1002/0471250953.bi1110s43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122. doi: 10.1186/s13059-016-0974-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Paila U, Chapman BA, Kirchner R, Quinlan AR. GEMINI: integrative exploration of genetic variation and genome annotations. PLoS Comput Biol. 2013;9(7):e1003153. doi: 10.1371/journal.pcbi.1003153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. Hum Mutat. 2013;34:E2393–E2402. doi: 10.1002/humu.22376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Albani D, Roiter I, Artuso V, Batelli S, Prato F, Pesaresi M, et al. Presenilin-1 mutation E318G and familial Alzheimer’s disease in the Italian population. Neurobiol Aging. 2007;28:1682–1688. doi: 10.1016/j.neurobiolaging.2006.07.003. [DOI] [PubMed] [Google Scholar]
  • 18.Haugabook SJ, Yager DM, Eckman EA, Golde TE, Younkin SG, Eckman CB. High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer’s amyloid β peptide (Aβ) J Neurosci Methods. 2001;108:171–179. doi: 10.1016/S0165-0270(01)00388-0. [DOI] [PubMed] [Google Scholar]
  • 19.Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39:409–421. doi: 10.1016/S0896-6273(03)00434-3. [DOI] [PubMed] [Google Scholar]
  • 20.Shimizu-Nishikawa K, Kajiwara K, Sugaya E. Cloning and characterization of seizure-related gene, SEZ-6. Biochem Biophys Res Commun. 1995;216:382–389. doi: 10.1006/bbrc.1995.2635. [DOI] [PubMed] [Google Scholar]
  • 21.Bork P, Beckmann G. The CUB domain: a widespread module in developmentally regulated proteins. J Mol Biol. 1993;231:539–545. doi: 10.1006/jmbi.1993.1305. [DOI] [PubMed] [Google Scholar]
  • 22.Alzheimer Disease & Frontotemporal Dementia Mutation Database (AD&FTDMDB). http://www.molgen.ua.ac.be/ADmutations/. Accessed 21 May 2018.
  • 23.Pigoni M, Wanngren J, Kuhn PH, Munro KM, Gunnersen JM, Takeshima H, et al. Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. Mol Neurodegener. 2016;11:67. doi: 10.1186/s13024-016-0134-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zhu K, Xiang X, Filser S, Marinković P, Dorostkar MM, Crux S, et al. Β-site amyloid precursor protein cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure protein 6. Biol Psychiatry. 2018;83:428–437. doi: 10.1016/j.biopsych.2016.12.023. [DOI] [PubMed] [Google Scholar]
  • 25.Khoonsari PE, Häggmark A, Lönnberg M, Mikus M, Kilander L, Lannfelt L, et al. Analysis of the cerebrospinal fluid proteome in Alzheimer’s disease. PLoS One. 2016;11:e0150672. doi: 10.1371/journal.pone.0150672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Yu ZL, Jiang JM, Wu DH, Xie HJ, Jiang JJ, Zhou L, et al. Febrile seizures are associated with mutation of seizure-related (SEZ) 6, a brain-specific gene. J Neurosci Res. 2007;85:166–172. doi: 10.1002/jnr.21103. [DOI] [PubMed] [Google Scholar]
  • 27.Mulley JC, Iona X, Hodgson B, Heron SE, Berkovic SF, Scheffer IE, et al. The role of seizure-related SEZ6 as a susceptibility gene in febrile seizures. Neurol Res Int. 2011;2011:917565. doi: 10.1155/2011/917565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ambalavanan A, Girard SL, Ahn K, Zhou S, Dionne-Laporte A, Spiegelman D, et al. De novo variants in sporadic cases of childhood onset schizophrenia. Eur J Hum Genet. 2016;24:944–948. doi: 10.1038/ejhg.2015.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.1000 Genomes Browser. https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/. Accessed 18 July 2017.
  • 30.Sarkar S, Roy BC, Hatano N, Aoyagi T, Gohji K, Kiyama R. A novel ankyrin repeat-containing gene (Kank) located at 9p24 is a growth suppressor of renal cell carcinoma. J Biol Chem. 2002;277:36585–36591. doi: 10.1074/jbc.M204244200. [DOI] [PubMed] [Google Scholar]
  • 31.Zhu Y, Kakinuma N, Wang Y, Kiyama R. Kank proteins: a new family of ankyrin-repeat domain-containing proteins. Biochim Biophys Acta. 2008;1780:128–133. doi: 10.1016/j.bbagen.2007.09.017. [DOI] [PubMed] [Google Scholar]
  • 32.Gee HY, Zhang F, Ashraf S, Kohl S, Sadowski CE, Vega-Warner V, et al. KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest. 2015;125:2375–2384. doi: 10.1172/JCI79504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lerer I, Sagi M, Meiner V, Cohen T, Zlotogora J, Abeliovich D. Deletion of the ANKRD15 gene at 9p24.3 causes parent-of-origin-dependent inheritance of familial cerebral palsy. Hum Mol Genet. 2005;14:3911–3920. doi: 10.1093/hmg/ddi415. [DOI] [PubMed] [Google Scholar]
  • 34.Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Jr, Eckman C, et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β APP717) mutants. Science. 1994;264:1336–1340. doi: 10.1126/science.8191290. [DOI] [PubMed] [Google Scholar]
  • 35.Bentahir M, Nyabi O, Verhamme J, Tolia A, Horré K, Wiltfang J, et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006;96:732–742. doi: 10.1111/j.1471-4159.2005.03578.x. [DOI] [PubMed] [Google Scholar]
  • 36.Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease. J Exp Med. 2015;212:2003–2013. doi: 10.1084/jem.20150892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kim MH, Gunnersen JM, Tan SS. Localized expression of the seizure-related gene SEZ-6 in developing and adult forebrains. Mech Dev. 2002;118:171–174. doi: 10.1016/S0925-4773(02)00238-1. [DOI] [PubMed] [Google Scholar]
  • 38.Osaki G, Mitsui S, Yuri K. The distribution of the seizure-related gene 6 (Sez-6) protein during postnatal development of the mouse forebrain suggests multiple functions for this protein: an analysis using a new antibody. Brain Res. 2011;1386:58–69. doi: 10.1016/j.brainres.2011.02.025. [DOI] [PubMed] [Google Scholar]
  • 39.Gunnersen JM, Kim MH, Fuller SJ, De Silva M, Britto JM, Hammond VE, et al. Sez-6 proteins affect dendritic arborization patterns and excitability of cortical pyramidal neurons. Neuron. 2007;56:621–639. doi: 10.1016/j.neuron.2007.09.018. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional file 1: (85.9KB, xlsx)

Table reporting the sequencing results of DNA from PR family members and unrelated sporadic AD cases, including only rare variants in the European population (frequency less than 1%) [low frequency page]. The same reults were further filtered to show variants with predicted damaging action [predicted damage page]. (XLSX 85 kb)

Data Availability Statement

Exome sequencing data files were uploaded to the European Nucleotide Archive (https://www.ebi.ac.uk/ena) with accession numbers pending.

Articles from Alzheimer's Research & Therapy are provided here courtesy of BMC

RESOURCES